(Q35173609)

6 August 2017

1 reference

title

Vasopressin: a new target for the treatment of heart failure (English)

1 reference

6 August 2017

0 references

0 references

6

Mihai Gheorghiade

1 reference

6 August 2017

Craig R Lee

1

1 reference

ORCID Public Data File 2021

Christopher M O'Connor

5

object named as

Christopher M O'connor

1 reference

6 August 2017

Michael L Watkins

2

1 reference

6 August 2017

J Herbert Patterson

3

1 reference

6 August 2017

Wendy Gattis

4

1 reference

6 August 2017

Kirkwood F Adams

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

published in

American Heart Journal

1 reference

6 August 2017

volume

146

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

9-18

1 reference

Hormones and hemodynamics in heart failure

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Vasopressin as vasopressor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Increased plasma arginine vasopressin levels in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Arginine vasopressin and the renal response to water loading in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2802%2994708-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(02)94708-3

1 reference

6 August 2017

1 reference